Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study

ConclusionsOur findings show that polymorphism analysis ofHIF-1 α,VEGF, andVEGFR genes may represent a prognostic panel to better identify HCC patients who are more likely to benefit from sorafenib treatment.

Source: Targeted Oncology - February 3, 2020 Category: Cancer & Oncology Source Type: research